VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
64Cu-Dotatate
Phase 1
Radiopharmaceutical
U
University of Wisconsin, Madison
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[2]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neuroendocrine Tumors
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neuroendocrine Tumors
Phase 1
Completed
Clinical
Trials by Indication
[1]
Neuroendocrine Tumors
1 trial
Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
Completed
·
U
University of Wisconsin, Madison
·
Phase 1
·
NCT06122610
·
4 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for 64Cu-Dotatate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform
—
Drug–disease associations for 64Cu-Dotatate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR
—
University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Radiopharmaceutical
Highest Phase
Phase 1
[1]
Company
U
University of Wisconsin, Madison
Related News